Replimune Group, Inc. (NASDAQ:REPL) Receives $17.29 Consensus PT from Brokerages

Replimune Group, Inc. (NASDAQ:REPL) has received a consensus recommendation of “Buy” from the eight brokerages that are covering the stock, MarketBeat reports. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $17.29.

Several brokerages have recently weighed in on REPL. JPMorgan Chase & Co. increased their target price on shares of Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 24th. HC Wainwright restated a “buy” rating and set a $17.00 price target on shares of Replimune Group in a research note on Friday, November 22nd. Jefferies Financial Group boosted their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, December 4th. Finally, BMO Capital Markets raised their target price on shares of Replimune Group from $14.00 to $18.00 and gave the stock an “outperform” rating in a research note on Friday, November 22nd.

Replimune Group Trading Up 0.5 %

REPL opened at $12.62 on Wednesday. The company has a quick ratio of 10.11, a current ratio of 10.11 and a debt-to-equity ratio of 0.18. Replimune Group has a 52 week low of $4.92 and a 52 week high of $17.00. The business’s 50 day moving average is $12.44 and its two-hundred day moving average is $11.01. The firm has a market cap of $863.42 million, a price-to-earnings ratio of -4.14 and a beta of 1.26.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. On average, research analysts predict that Replimune Group will post -2.91 EPS for the current year.

Insiders Place Their Bets

In other news, insider Konstantinos Xynos sold 7,246 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the sale, the insider now directly owns 109,885 shares in the company, valued at $1,184,560.30. This represents a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Sushil Patel sold 10,000 shares of Replimune Group stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $12.42, for a total value of $124,200.00. Following the transaction, the chief executive officer now owns 202,014 shares of the company’s stock, valued at $2,509,013.88. This represents a 4.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 8.80% of the stock is currently owned by company insiders.

Institutional Trading of Replimune Group

Several institutional investors and hedge funds have recently made changes to their positions in REPL. Charles Schwab Investment Management Inc. raised its stake in Replimune Group by 12.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 484,797 shares of the company’s stock valued at $5,313,000 after purchasing an additional 52,498 shares during the last quarter. Barclays PLC raised its position in shares of Replimune Group by 165.5% in the third quarter. Barclays PLC now owns 158,491 shares of the company’s stock valued at $1,738,000 after buying an additional 98,791 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Replimune Group by 17.9% during the third quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock valued at $15,657,000 after buying an additional 217,308 shares during the period. LMR Partners LLP boosted its position in Replimune Group by 145.8% during the third quarter. LMR Partners LLP now owns 82,479 shares of the company’s stock worth $904,000 after acquiring an additional 48,920 shares during the last quarter. Finally, Millennium Management LLC grew its stake in Replimune Group by 575.1% in the 2nd quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock worth $28,062,000 after acquiring an additional 2,656,173 shares during the period. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.